General Information of Drug (ID: DMCS4BL)

Drug Name
J-104870 Drug Info
Synonyms
145-13-1; 3-Hydroxypregn-5-en-20-one; 1-(3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)ethanon; 1-(3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethanone; .DELTA.5-Pregnenolone; 5-Pregnene-3-ol-20-one; 5-Pregnen-3.beta.-ol-20-one; delta5-Pregnen-3beta-ol-20-one; Pregn-5-en-20-one, 3-hydroxy-; 3.beta.-Hydroxypregn-5-en-20-one; Pregn-5-en-20-one, 3.beta.-hydroxy-; AC1L1AKE; AC1Q1K1J; CHEMBL14116
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9807770
TTD Drug ID
DMCS4BL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NEUROPEPTIDE-Y DMINQP1 N. A. N. A. Phase 2 [2]
H-409/22 DMYJ9CF Cardiovascular disease BA00-BE2Z Discontinued in Phase 2 [3]
PD-160170 DMB9Z4C Heart disease BA41-BA42 Preclinical [4]
GI-264879A DM25N8B Obesity 5B81 Preclinical [4]
SR 120819A DMETDFM Eating disorder 6B82 Terminated [5]
BIBP 3226 DMYBR9D Hypertension BA00-BA04 Terminated [6]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [7]
H-[Trp-Arg-Nva-Arg-Tyr]3-NH2 DMKH8PF Discovery agent N.A. Investigative [8]
Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DM4SWQA Discovery agent N.A. Investigative [8]
Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DMBERSG Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neuropeptide Y receptor type 1 (NPY1R) TTRK9JT NPY1R_HUMAN Antagonist [1]

References

1 The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability. Biochem Biophys Res Commun. 1999 Dec 9;266(1):88-91.
2 5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor. J Nat Prod. 2009 Dec;72(12):2172-6.
3 In vivo characterization of the novel neuropeptide Y Y1 receptor antagonist H 409/22. J Cardiovasc Pharmacol. 2000 Oct;36(4):516-25.
4 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
5 SR 120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist. FEBS Lett. 1995 Apr 3;362(2):192-6.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 305).
7 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
8 Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.